Mossman Ulcer

Mossman ulcer is a slow-growing bacterial infection that starts as a painless lump, patch, or swelling under the skin. Over weeks, the skin thins and breaks down into a painless open sore (ulcer) with undermined edges. The germ makes a toxin (mycolactone) that kills tissue and switches off pain, so people often do not feel sick or feverish at first. Without timely treatment, the ulcer can enlarge, destroy deeper tissues, involve bone, and leave scars and joint stiffness. Early antibiotics cure most cases; wound care and sometimes surgery help the skin heal with less scarring. World Health Organization+1

Mossman ulcer is an infection of the skin caused by a bacteria named Mycobacterium ulcerans. The germ makes a toxin that slowly destroys skin and the tissue under the skin, so a small painless lump can turn into a big open sore over weeks. These sores often have edges that are “undermined,” meaning the skin overhangs the cavity. People usually feel well and have no fever. Without quick treatment, the ulcer can get larger, involve muscle or bone, and leave scars and stiffness. Doctors diagnose it by its look and confirm it with a PCR test that looks for a DNA target called IS2404. The best treatment today is 8 weeks of two oral antibiotics (rifampicin once daily + clarithromycin twice daily), plus careful wound care and sometimes surgery to remove dead tissue or to close large defects. Wikipedia+2World Health Organization+2

Other names

Doctors and public health services use several names for the same disease:

• Buruli ulcer (global name)

• Mossman ulcer and Daintree ulcer (Far North Queensland, Australia)

• Bairnsdale ulcer (Victoria, Australia)

• Less commonly: Searls’ ulcer, Kumasi ulcer (local historic names)

These are all the same infection caused by Mycobacterium ulcerans. NCBI+2Medscape+2

Types

Doctors describe Mossman/Buruli ulcer by form, stage, and extent. Using this language helps pick the right test and treatment.

1. Non-ulcerative forms (early disease)

• Nodule: a firm, painless, mobile lump under the skin.

• Plaque: a broad, raised, firm area of swelling.

• Edematous form: diffuse, painless swelling of a limb or face that looks like cellulitis but without much pain or fever.
  These early forms often progress to an ulcer if untreated. World Health Organization

2. Ulcerative form (classic appearance)

• A painless ulcer with undermined, overhanging edges and a necrotic (dead tissue) base, usually on arms or legs. It may ooze but is often surprisingly not very painful unless secondarily infected. World Health Organization

3. Extent/severity (WHO categories)

• Category I: single small lesion (<5 cm).

• Category II: single 5–15 cm lesion or multiple small lesions.

• Category III: large (>15 cm), multiple, or lesions with bone/joint involvement or critical sites (eye, genitals).
  These categories guide antibiotics, wound care, and whether surgery is needed. World Health Organization

4. Complicated forms

• Osteomyelitis (bone infection), joint contractures, and functional disability when diagnosis is late. World Health Organization

---

Causes

Strictly speaking, the cause is infection with Mycobacterium ulcerans. Everything else below are exposures and risk factors that make infection more likely or allow it to progress. World Health Organization

1. Exposure in an endemic area (parts of coastal Victoria; Far North Queensland including Mossman–Daintree; West Africa; PNG; Japan). Being in these places raises risk. RACGP+1

2. Mosquito exposure in Australian settings (increasing evidence that mosquitoes help move the bacterium between the environment, possums, and people). The Guardian+1

3. Contact with contaminated environment such as wetlands, slow-moving or stagnant water, swamps, and damp soils where the bacterium persists. World Health Organization

4. Possum reservoirs in Australia (the bacterium has been detected in possum feces; environmental cycle likely involves possums and mosquitoes). The Guardian+1

5. Small skin injuries (scratches, insect bites) that give germs a way in. World Health Organization

6. Outdoor activities (gardening, camping, hiking, fishing) in endemic areas without protective clothing/repellent. RACGP

7. No or inconsistent insect-bite protection (no repellent, uncovered limbs at dusk). news.com.au

8. Delayed health care (the toxin keeps lesions painless, so people wait, letting disease advance). World Health Organization

9. Older age (notification rates are higher in people >60 years in Victoria). news.com.au

10. Underlying diabetes (slows wound healing; increases risk of secondary infection). General wound-risk inference aligned with clinical experience; BU-specific guidance still focuses on early antibiotics regardless of comorbidity. World Health Organization

11. Immune suppression (e.g., long-term steroids, chemotherapy, advanced HIV) may worsen severity or slow healing. World Health Organization

12. Poor wound hygiene after minor trauma in endemic settings. World Health Organization

13. Living near or visiting new transmission zones during local outbreaks (e.g., suburban Melbourne spread). The Guardian

14. Lack of awareness among travelers and clinicians (misdiagnosis as spider bite or cellulitis delays proper antibiotics). RACGP

15. History of previous BU (scars may be vulnerable; reinfection can occur in endemic areas). World Health Organization

16. Environmental changes such as flooding or construction that alter mosquito habitats (inferred from public health messaging on vector control in Victorian clusters). news.com.au

17. Handling sick wildlife (public advisories include avoiding contact with sick possums). news.com.au

18. Occupational exposure (farmers, landscapers, rangers) working unprotected in risk zones. RACGP

19. Travel to endemic regions with unprotected outdoor activities, then returning home (so disease appears outside the hotspot). RACGP

20. Not seeking testing when a “bite” does not heal (painless, enlarging lesion for weeks is a red flag in endemic areas). RACGP

---

Symptoms and signs

1. Painless lump (nodule) that slowly enlarges. The lack of pain is typical. World Health Organization

2. Firm, raised patch (plaque) of skin, often on arms or legs. World Health Organization

3. Painless swelling (edema) of a limb or face that looks like cellulitis but without fever. World Health Organization

4. Painless ulcer with undermined edges and a yellowish necrotic base. World Health Organization

5. Minimal or no fever and a general feeling of being well despite the ulcer. World Health Organization

6. Slow but relentless expansion of the sore over weeks to months. World Health Organization

7. Mild or no tenderness unless secondarily infected with common bacteria. World Health Organization

8. Drainage or weeping from the ulcer, sometimes with odor if superinfected. World Health Organization

9. Skin discoloration around the lesion (reddish, purplish, or pale atrophic skin). World Health Organization

10. Regional lymph nodes usually not very enlarged early on (different from many other infections). World Health Organization

11. Multiple lesions in some cases. World Health Organization

12. Functional limitation near joints (stiffness, reduced movement) as tissue is destroyed. World Health Organization

13. Scarring after healing, which can contract and limit joint motion. World Health Organization

14. Bone pain or tenderness if osteomyelitis develops in advanced disease. World Health Organization

15. Psychological stress and stigma because the wound looks alarming and can take time to heal. Wikipedia

---

Diagnostic tests

Key idea: In a person from (or who visited) an endemic area with a painless, slowly enlarging ulcer or swelling, doctors suspect Buruli/Mossman ulcer clinically and confirm it in the lab. The most reliable, fast test is PCR on a swab from the undermined edge or a tissue sample. Other methods help when PCR is not available or for staging/complications. World Health Organization+1

A) Physical examination (bedside assessment)

1. Lesion inspection: doctor looks for painless ulcer with undermined edges or early nodule/plaque/edema pattern typical of BU. This raises clinical suspicion. World Health Organization

2. Size measurement and mapping: measuring the longest diameter and photographing over time shows progression or response to treatment.

3. Palpation (gentle feel): checks for tenderness (usually little) and tissue loss under the skin, which suggests the toxin’s effect.

4. Joint range-of-motion check: stiffness near elbows, knees, or ankles suggests functional risk and guides early physiotherapy referral.

5. Lymph node exam: often small or not very tender, which helps distinguish from cellulitis.

(The five exam steps above are clinical best practice; the specific “signatures” of painless undermined ulcers and early non-ulcer forms are emphasized by WHO.) World Health Organization

B) “Manual” tests (simple bedside procedures without machines)

6. Wound edge swab collection: a trained clinician rotates a swab beneath the undermined edge to collect bacteria for PCR. Technique matters for sensitivity. CDC

7. Needle aspiration/fine-needle sampling of early nodules or plaques to send for PCR/microscopy when no ulcer is present yet. World Health Organization

8. Probe-to-bone test (sterile blunt probe) if deep or chronic ulcer raises concern for bone involvement—a simple way to decide if imaging is needed (supportive, not specific to BU).

9. Ankle-brachial pressure or capillary refill (when lesions are on the leg) to screen perfusion, which affects wound healing (supportive test, not specific).

10. Wound odor/appearance assessment to guide secondary bacterial culture if superinfection is suspected (helps choose additional antibiotics when needed).

(Items 6–7 link directly to BU confirmation steps; 8–10 are practical bedside checks that guide staging and wound care.) World Health Organization

C) Laboratory and pathological tests (confirm the diagnosis)

11. IS2404 PCR (polymerase chain reaction) on swab or tissue: gold-standard rapid test for M. ulcerans. Highly sensitive/specific and recommended by WHO/CDC. World Health Organization+1

12. Direct smear microscopy for acid-fast bacilli (AFB) using Ziehl-Neelsen staining. Faster and cheaper but less sensitive than PCR; helpful in some settings. World Health Organization

13. Culture of M. ulcerans from tissue: confirms the organism but is slow and technically difficult (prefers 29–33 °C, low oxygen). Mainly used in reference labs. World Health Organization

14. Histopathology (biopsy): shows necrosis of subcutaneous fat, minimal inflammation, and clusters of AFB, supporting diagnosis and ruling out other diseases. CDC

15. Routine wound swab culture for other bacteria when there is secondary infection (e.g., Staphylococcus aureus, streptococci). This does not prove BU but guides add-on antibiotics if needed.

16. Basic blood tests (full blood count, CRP): often near normal in uncomplicated BU; help assess general health and readiness for treatment. World Health Organization

D) Electrodiagnostic tests

17. Usually not required. BU is a skin/soft-tissue infection; nerve tests (e.g., nerve conduction studies, EMG) are not part of routine diagnosis. They might be used rarely if a very large lesion or scarring suggests nerve compression and the clinician needs to document neuropathy for rehab planning. (This category is included here only because you asked for it; most cases do not need electrodiagnostics.) World Health Organization

E) Imaging tests (to check depth and complications)

18. Plain X-ray of the affected area if bone involvement is suspected (osteomyelitis, periosteal reaction). Helpful in advanced disease. World Health Organization

19. Ultrasound to define edema, fluid collections, or abscesses around a lesion; can guide needle aspiration. (Used in many centers as a quick staging tool.) RACGP

20. MRI for detailed mapping when the lesion is large, near a joint, or surgery is being planned; shows soft-tissue planes and bone marrow involvement more clearly than other tests. (Reserved for selected cases.) RACGP

Non-pharmacological treatments (therapies & other measures)

1) Early wound cleansing and protection
Gently wash the lesion with clean water or normal saline and cover with a sterile, non-adherent dressing. Keeping the wound clean lowers the risk of secondary infection and helps the antibiotics work. Avoid harsh chemicals that can damage healing tissue. Daily or every-other-day dressing changes, guided by exudate, are typical. This basic care limits spread, protects surrounding skin, and improves comfort. World Health Organization

Purpose: Reduce germ load, protect tissue, and prevent new infection.
Mechanism: Mechanical removal of debris; moisture-balanced dressings support granulation and re-epithelialization. PMC

2) Moisture-balance dressings
Use non-adherent, moisture-retentive dressings (e.g., hydrofiber or foam) to maintain a moist but not wet bed. Moist wound healing supports cell migration and collagen deposition, speeding closure and reducing pain compared with dry gauze. Switch dressings as exudate changes during therapy. PMC

Purpose: Speed healing and comfort.
Mechanism: Optimizes moisture and oxygen at the surface to support keratinocyte and fibroblast activity. PMC

3) Debridement of devitalized tissue (selective)
When safe (and not during acute paradoxical inflammation), careful removal of necrotic tissue decreases bacterial load and biofilm, facilitates granulation, and improves dressing contact. Debridement is tailored and often staged, coordinated with antibiotics. PMC

Purpose: Convert a chronic, contaminated wound into a clean, healing wound.
Mechanism: Eliminates non-viable tissue that fuels inflammation and harbors microbes. PMC

4) Negative pressure wound therapy (NPWT)
For large, clean wounds, NPWT can manage exudate, shrink wound size, and prepare for grafting. It’s used after initial infection control and debridement. PMC

Purpose: Accelerate granulation and wound contraction.
Mechanism: Sub-atmospheric pressure improves perfusion and mechanically stimulates granulation tissue. PMC

5) Splinting and gentle range-of-motion
Ulcers near joints can scar and cause contractures. Early splinting in functional position and supervised, gentle exercises preserve movement while protecting the wound. PMC

Purpose: Prevent stiffness and disability.
Mechanism: Maintains tendon glide and joint capsule length while minimizing traction on healing tissue. PMC

6) Edema control and limb elevation
Swelling around ulcers slows healing. Elevation, compression (if appropriate and not painful), and movement reduce edema, improve oxygen delivery, and enhance antibiotic penetration. PMC

Purpose: Improve microcirculation and healing speed.
Mechanism: Decreases interstitial pressure and increases capillary perfusion. PMC

7) Pain control with non-drug strategies
Cool saline soaks before dressing changes, careful handling, and relaxation techniques reduce anxiety and procedural pain and may lower analgesic needs. PMC

Purpose: Comfort and adherence to care.
Mechanism: Desensitization and reduced nociceptor firing via temperature and gentle technique. PMC

8) Nutritional optimization
Adequate calories (30–35 kcal/kg/day), protein (≥1.25–1.5 g/kg/day), and key micronutrients (vitamin C, vitamin A, zinc, arginine, omega-3) support collagen synthesis and immunity; screen for and correct deficiencies. PMC+3E-ACNM+3Cambridge Media Journals+3

Purpose: Provide building blocks for tissue repair.
Mechanism: Protein and arginine fuel collagen and nitric-oxide–mediated healing; vitamin C and zinc enable collagen cross-linking and immune function; omega-3s modulate excessive inflammation. PMC+1

9) Psychosocial support and stigma reduction
Buruli ulcer can cause shame and social isolation. Clear education, counseling, and community engagement improve early presentation and adherence and reduce harmful traditional practices. Wikipedia

Purpose: Improve mental health and treatment success.
Mechanism: Education and social support counter fear and delay. Wikipedia

10) Household and wound-hygiene education
Teach hand hygiene, safe dressing disposal, and avoiding unsterile topical remedies or scarification. Family instruction reduces contamination and speeds healing. World Health Organization

Purpose: Prevent secondary infection and new cases.
Mechanism: Breaks transmission opportunities and protects the wound environment. World Health Organization

11) Early presentation campaigns (community health)
Community messages in endemic areas about “painless swelling that becomes a sore” promote early care, which shortens treatment and lowers disability. World Health Organization

Purpose: Catch disease early.
Mechanism: Reduces time to antibiotics and prevents large ulcers. World Health Organization

12) Avoid trauma and pressure over the lesion
Cushion bony areas, adjust footwear, and teach safe movement to avoid shearing and enlargement of undermined edges. PMC

Purpose: Preserve fragile margins and speed closure.
Mechanism: Minimizes mechanical disruption and micro-ischemia. PMC

13) Sun and heat protection of scars
After healing, protect immature scars from sunlight and heat to prevent burn and hyperpigmentation; moisturize to maintain pliability. PMC

Purpose: Better scar quality and function.
Mechanism: Limits UV-driven pigment change and collagen damage. PMC

14) Physiotherapy after closure
Once closed, progressive stretching and strength work restore range, reduce contracture risk, and return function for work and school. PMC

Purpose: Functional recovery.
Mechanism: Remodeling collagen along lines of stress. PMC

15) Offloading devices (site-specific)
For plantar or weight-bearing ulcers, temporary offloading (e.g., crutches, modified footwear) limits shear and pressure that delay healing. PMC

Purpose: Support closure in high-stress sites.
Mechanism: Reduces mechanical load on the wound bed. PMC

16) Treat secondary bacterial infection promptly
If the ulcer becomes red, foul-smelling, or painful, culture if possible and treat per local guidance to prevent sepsis and tissue loss. This is adjunctive to specific M. ulcerans therapy. PMC

Purpose: Control non-mycobacterial superinfection.
Mechanism: Targeted antibiotics reduce competing pathogens and inflammation. PMC

17) Tetanus prophylaxis per guidelines
Dirty ulcers increase tetanus risk; check and update vaccination status during care. PMC

Purpose: Prevent tetanus.
Mechanism: Induced antitoxin protects against C. tetani. PMC

18) Coordinated multidisciplinary care
Combine infectious-disease, wound-care, surgical, and rehab input—especially for large, joint-adjacent, or facial lesions—to minimize disability. PMC

Purpose: Optimize outcomes.
Mechanism: Team decisions time surgery and rehab with antibiotics. PMC

19) Laboratory confirmation when available
Send swab/FNA from undermined edge for IS2404 PCR; use microscopy when PCR is not available. Early confirmation guides standardized therapy. WHO | Regional Office for Africa

Purpose: Accurate diagnosis.
Mechanism: DNA amplification detects M. ulcerans specifically and sensitively. WHO | Regional Office for Africa

20) Programmatic follow-up through healing
Schedule checks during and after the 8-week regimen to detect paradoxical reactions, manage dressings, and plan rehab or surgery. World Health Organization

---

Drug treatments

Clinical anchor: WHO and modern Australian guidance recommend rifampicin + clarithromycin for 8 weeks as first-line (fully oral). Other agents below are used as partners or alternatives based on setting, age, and tolerance; some (e.g., streptomycin) are older and now largely avoided because of toxicity or the availability of all-oral regimens. Always combine two active drugs against M. ulcerans. PMC+3WHO | Regional Office for Africa+3World Health Organization+3

1) Rifampicin (RIF) — core drug
Class: Rifamycin. Dose: Adults commonly 10 mg/kg once daily (max ~600 mg) for 8 weeks in BU regimens. Timing: Morning dosing standard. Purpose: Bactericidal backbone against mycobacteria. Mechanism: Inhibits DNA-dependent RNA polymerase, blocking transcription. Side effects: Hepatotoxicity, orange discoloration of fluids, major drug–drug interactions via enzyme induction (e.g., warfarin, many antivirals). (Use per BU guidelines; FDA label informs safety/pharmacology.) WHO | Regional Office for Africa+2World Health Organization+2

2) Clarithromycin (CLR) — partner in first-line oral regimen
Class: Macrolide. Dose: 7.5 mg/kg twice daily (or extended-release 15 mg/kg once daily) for 8 weeks. Purpose: Companion to rifampicin to improve cure and prevent resistance. Mechanism: 50S ribosomal binding; inhibits protein synthesis. Side effects: GI upset, taste changes, QT-prolongation risk, CYP3A interactions. (Label used for safety; dosing per BU guidance.) WHO | Regional Office for Africa+1

3) Moxifloxacin (MOX) — adult alternative partner
Class: Fluoroquinolone. Dose: 400 mg once daily for 8 weeks (adult alternative with rifampicin). Purpose: Option when macrolides are not tolerated. Mechanism: Inhibits DNA gyrase/topoisomerase IV. Side effects: Tendon injury, QT prolongation, CNS effects; avoid in growing children. WHO | Regional Office for Africa+1

4) Ciprofloxacin (CIP) — alternative fluoroquinolone
Class: Fluoroquinolone. Dose: Common adult dosing 500–750 mg twice daily when used; partner with rifampicin. Purpose: Observational support as alternative; use tailored to setting. Mechanism/risks: DNA gyrase inhibition; tendon, neuropathy, CNS adverse effects. Cochrane Library+1

5) Azithromycin (AZM) — pediatric alternative
Class: Macrolide. Dose: 10 mg/kg once daily (max 500 mg) as alternative partner in some pediatric centers. Purpose: Once-daily option when clarithromycin is not tolerated. Mechanism/risks: 50S binding; GI upset, QT risk. The Medical Journal of Australia+1

6) Levofloxacin (LEV) — alternative fluoroquinolone
Class: Fluoroquinolone. Dose: Typical adult 500–750 mg once daily where used with rifampicin. Purpose: Alternative when others unsuitable. Mechanism/risks: Topoisomerase inhibition; tendinopathy warnings as class-wide. PMC+1

7) Ethambutol (EMB) — occasional companion
Class: Antimycobacterial. Dose: Weight-based daily dosing; sometimes paired with rifampicin in older regimens or complex cases. Mechanism/risks: Inhibits arabinosyl transferases; optic neuritis monitoring. Wikipedia+1

8) Amikacin (AMK) — injectable (older/selected use)
Class: Aminoglycoside. Dose: IV/IM weight-based (e.g., 15 mg/kg/day in divided doses); historically used in combinations. Mechanism/risks: 30S ribosomal binding; nephro- and ototoxicity limit use vs all-oral regimens. Wikipedia+1

9) Streptomycin (STR) — injectable (largely avoided now)
Class: Aminoglycoside. Dose: IM, weight-based; formerly standard with rifampicin for 8 weeks but now replaced by oral regimens due to toxicity/administration burden. Mechanism/risks: 30S binding; ototoxicity, nephrotoxicity, fetal harm. dndi.org+2The Lancet+2

10) Trimethoprim–sulfamethoxazole (TMP-SMX) — adjunct where used
Class: Antifolate combination. Dose: Standard doses (e.g., DS 800/160 mg bid) in select protocols as partner with rifampicin when others not possible. Mechanism/risks: Sequential folate pathway block; hypersensitivity, hyperkalemia. Evidence in BU is limited. PMC+1

11) Levofloxacin–rifampicin adult regimen (combined concept)
Note: Some services substitute levofloxacin for moxifloxacin based on availability/tolerance; follow local expertise. Label safety and class cautions apply. RACGP+1

12) Ciprofloxacin–rifampicin adult regimen (combined concept)
Used in selected contexts as a practical alternative; monitor for fluoroquinolone adverse effects and rifampicin interactions. Cochrane Library+1

13) Clarithromycin (extended-release) once-daily option
Once-daily ER clarithromycin can simplify dosing; confirm pediatric dosing if used. WHO | Regional Office for Africa

14) Azithromycin once-daily pediatric alternative (combined concept)
Centers using azithromycin with rifampicin cite simpler dosing; follow specialist protocols. The Medical Journal of Australia

15) Moxifloxacin as step-down after intolerance (concept)
If clarithromycin intolerance occurs, adult services may step to moxifloxacin with rifampicin; ECG/QT risk considered. WHO | Regional Office for Africa

16) Ethambutol add-on in complex disease (concept)
Occasionally used when extensive disease or drug issues arise; check vision monthly. Wikipedia

17) Amikacin short course when oral not feasible (legacy)
Reserved scenarios; ototoxicity risk and monitoring required—reason modern care prefers all-oral regimens. PMC

18) Streptomycin legacy regimen (no longer preferred)
Documented non-inferiority of all-oral rifampicin–clarithromycin vs streptomycin–rifampicin supports avoiding injectables. The Lancet

19) Supportive analgesics (paracetamol/NSAIDs) with caution
Used symptomatically; not anti-M. ulcerans, but improve comfort to maintain care. (Standard labels apply; not specific to BU.) PMC

20) Antihistamines/anti-itch for dressing comfort
Adjuncts for itch/sleep when needed; not disease-specific. Use shortest effective course. PMC

⚠️ Important: FDA labels above provide safety/pharmacology; indications for BU are off-label and based on WHO/consensus guidance and clinical studies; combine two active drugs and monitor for interactions and toxicity. WHO | Regional Office for Africa+2World Health Organization+2

---

Dietary molecular supplements

1) High-quality protein (with arginine emphasis)
Aim for ≥1.25–1.5 g/kg/day protein; include arginine-rich foods (nuts, legumes, poultry). Protein supplies amino acids for collagen and immune cells; arginine supports nitric-oxide-mediated perfusion and collagen deposition. Specialized oral supplements that include arginine have improved pressure-ulcer healing in trials. E-ACNM+1

Dose: Meet daily protein targets; arginine often 4–9 g/day in clinical nutrition formulas (follow product guidance).
Function/mechanism: Collagen substrate; arginine boosts immune function and wound repair. PMC

2) Vitamin C
Vitamin C is essential for collagen cross-linking and acts as an antioxidant. Supplementation improves healing in some ulcer settings when intake is low. PMC
Dose: Common clinical practice 200–500 mg/day when deficient (individualize).
Function/mechanism: Cofactor for prolyl/lysyl hydroxylases; supports neutrophil function. Cambridge Media Journals

3) Zinc
Zinc deficiency impairs epithelialization and immunity; correcting deficiency improves healing. E-ACNM
Dose: Replace deficiency short-term (e.g., 15–30 mg elemental/day); avoid long courses without monitoring copper.
Mechanism: Enzyme cofactor in DNA synthesis and keratinocyte migration. Cambridge Media Journals

4) Vitamin A
Supports epithelial growth and immune function; deficiency worsens wound outcomes. ScienceDirect
Dose: Dietary intake or short targeted supplements in deficiency states (medical supervision).
Mechanism: Regulates keratinocyte differentiation and collagen synthesis. ResearchGate

5) Omega-3 fatty acids (EPA/DHA)
When paired with arginine, omega-3s reduce surgical site infections and length of stay in several meta-analyses, suggesting benefit for inflammatory control in wound healing. PMC+1
Dose: Often 1–2 g/day combined EPA/DHA in nutrition formulas; tailor clinically.
Mechanism: Pro-resolving lipid mediators dampen excessive inflammation. PMC

6) Vitamin D
Low vitamin D status is linked to slower healing and impaired barrier function; correcting deficiency may aid repair. PMC+1
Dose: As per labs (e.g., 800–2000 IU/day maintenance; individualized repletion).
Mechanism: Modulates innate immunity, keratinocyte proliferation/differentiation. SpringerLink

7) Selenium
An antioxidant trace element supporting glutathione peroxidase; deficiency can impair immune response and healing. ScienceDirect
Dose: Replace dietary insufficiency (e.g., 50–100 mcg/day) short-term.
Mechanism: Limits oxidative damage in the wound environment. ScienceDirect

8) Probiotics (topical/oral, investigational)
Emerging studies show probiotic preparations can reduce pathogenic colonization and may speed closure, but strains/doses vary and standards are evolving. Consider only as adjuncts. PMC+2PMC+2
Dose: Product-specific; topical gels used in studies.
Mechanism: Microbiome modulation, bacteriocin production, immune tuning. PMC

9) Polyphenols (e.g., curcumin) — investigational
Polyphenols show anti-inflammatory and antioxidant effects that may aid healing; use as food-based support, not as a sole therapy. ScienceDirect
Dose: Dietary (spices/foods) or standardized extracts under supervision.
Mechanism: Modulates NF-κB and oxidative stress in wounds. ScienceDirect

10) Adequate total energy & fluids
Energy deficit halts repair; aim 30–35 kcal/kg/day and ~30 mL/kg/day fluids unless contraindicated. E-ACNM
Mechanism: Fuels protein synthesis and perfusion required for granulation. E-ACNM

---

Drugs for immunity booster / regenerative / stem-cell

There are no approved immune-boosting, regenerative, or stem-cell drugs for Buruli ulcer. Items below summarize research directions or general wound-healing adjuncts; use only in clinical trials or under specialist supervision. ASM Journals

1) Telacebec (Q203) — investigational
In preclinical/early studies, the cytochrome bc1 inhibitor telacebec shows potent anti-M. ulcerans activity and may shorten therapy when combined with rifampicin. Not approved for BU. ASM Journals
Dose/function/mechanism: Trial-defined; targets mycobacterial respiratory chain to enhance bacterial kill. ASM Journals

2) Epetraborole — investigational
Shows synergy in combinations (e.g., with moxifloxacin or omadacycline) against M. ulcerans in preclinical work; trial-only. ASM Journals
Mechanism: Inhibits leucyl-tRNA synthetase (protein synthesis). ASM Journals

3) Omadacycline — investigational combination partner
Studied in combinations for BU in preclinical models; no approved BU indication. ASM Journals

4) Platelet-rich plasma (PRP) — regenerative adjunct
Used for chronic wounds in general; may enhance granulation in clean, non-infected beds after bacterial control. Consider trial settings. MDPI

5) Topical growth factors (e.g., PDGF) — selective wound care
Used in some chronic wounds; not BU-specific and require clean beds and careful selection. MDPI

6) Cell-based therapies (e.g., mesenchymal stem cells) — experimental
Explored in chronic non-infectious wounds; not approved for BU; consider only in research. MDPI

---

Surgeries

1) Conservative surgical debridement
Selective removal of necrotic tissue/biofilm after antibiotics have begun. Why: Lowers bacterial burden, prepares a healthy bed, and reduces toxin-damaged tissue. PMC

2) Excision with primary closure
For small, well-demarcated lesions after adequate antibiotic course. Why: Shortens healing time and removes undermined edges that won’t contract. PMC

3) Split-thickness skin graft (STSG)
Covers large defects once clean and granulating. Why: Speeds epithelial coverage, reduces fluid loss and infection risk, restores function. PMC

4) Local or regional flap reconstruction
For deep or joint-adjacent defects where grafts won’t take. Why: Brings robust, vascularized tissue to cover exposed tendon/bone and permit movement. PMC

5) Contracture release and scar revision
After healing, for movement limitation or deformity. Why: Restores function and reduces disability. PMC

---

Prevention tips

1. Seek care early for any painless swelling that lasts more than a week in endemic areas. Early treatment prevents large ulcers. World Health Organization

2. Keep small cuts clean and covered after outdoor or freshwater exposure. World Health Organization

3. Wear protective clothing (long sleeves/pants) during dusk/dawn outdoor activity in endemic zones. RACGP

4. Use insect protection (repellent, screens) as local public-health advice suggests. RACGP

5. Avoid direct contact with stagnant or slow-moving waters in known hot-spots when you have open skin. RACGP

6. Do not apply unsterile herbs, ash, or caustics to lesions. World Health Organization

7. Complete the full 8-week antibiotic course if diagnosed. World Health Organization

8. Attend scheduled follow-ups; report any sudden redness/swelling (possible paradoxical reaction). PMC

9. Keep vaccinations (e.g., tetanus) up to date. PMC

10. Share education messages in your community to reduce delays and stigma. Wikipedia

---

When to see a doctor (now)

• You live in or recently visited an endemic area and have a painless lump, plaque, or swelling on a limb that does not improve in 1–2 weeks. Wikipedia

• An existing sore develops undermined edges or painless, widening tissue loss. Wikipedia

• There is new redness, pain, bad smell, or fever—signs of secondary infection. PMC

• The lesion is near an eye, joint, genitals, or shows exposed tendon/bone. These are high-risk sites needing specialist care. Wikipedia

• You cannot take, or are reacting to, prescribed antibiotics. World Health Organization

---

What to eat (“do” and “avoid”)

Eat more:

1. Lean proteins (fish, eggs, legumes, poultry) to hit daily protein targets for healing. E-ACNM

2. Citrus, guava, capsicum for vitamin C. PMC

3. Nuts/seeds, poultry, beans for arginine and zinc. PubMed

4. Oily fish (sardine, mackerel) for omega-3s. PMC

5. Vitamin-D–rich foods (fortified dairy/alternatives, eggs, fish) if status is low. PMC

Limit/avoid:

1. Alcohol (impairs immunity/wound healing). E-ACNM
2. Ultra-processed, high-sugar foods that displace protein/micronutrients. E-ACNM
3. Smoking or smokeless tobacco (vasoconstriction, delayed healing). E-ACNM
4. Unregulated “herbal” topical pastes on the ulcer (infection risk). World Health Organization
5. Excess zinc supplements beyond short corrective courses (risk of copper deficiency). E-ACNM

---

FAQs

1) Is Mossman ulcer the same as Buruli ulcer?
Yes—“Mossman ulcer” is a local Australian name for Buruli ulcer caused by M. ulcerans. NCBI

2) How is it caught?
Exact transmission is still being studied; environmental exposure in endemic areas is implicated; mosquitoes and possum reservoirs have been investigated locally. Avoiding skin trauma and prompt wound care are sensible. RACGP

3) Is it painful?
Often not at first; it’s typically painless until secondarily infected or very advanced. Wikipedia

4) How is it diagnosed?
Clinical exam plus lab confirmation by IS2404 PCR from the wound edge; microscopy can help where PCR is unavailable. WHO | Regional Office for Africa

5) What is the first-line treatment?
Eight weeks of oral rifampicin + clarithromycin, with careful wound care. World Health Organization

6) Are injections still needed?
Not usually—oral rifampicin/clarithromycin was non-inferior to rifampicin/streptomycin injections for early disease. The Lancet

7) Can children take the oral regimen?
Yes; pediatric doses are the same per kg as adults; azithromycin is an alternative partner in some centers if CLR not tolerated. The Medical Journal of Australia

8) How long before it heals?
Antibiotics are 8 weeks; complete skin closure can take longer depending on size/depth and need for grafts. PMC

9) What is a “paradoxical reaction”?
Temporary worsening (more redness/swelling) after starting antibiotics, due to immune response; it usually settles with continued therapy and wound care. Wikipedia

10) Will I have a scar?
Large/deep ulcers often scar; early treatment reduces size and disability; rehab helps function. PMC

11) Are there vaccines?
No BU-specific vaccine is available. World Health Organization

12) Can nutrition really help?
Yes—adequate energy/protein and key micronutrients (C, A, zinc, vitamin D; arginine; omega-3) support healing; they don’t replace antibiotics. E-ACNM+1

13) Do probiotics help?
They’re being studied as adjuncts; not standard yet. PMC

14) Can the ulcer come back?
Relapse can occur but is less likely with full antibiotic courses and follow-up; new lesions can also be new infections. PMC

15) Where can clinicians find detailed guidance?
WHO treatment and lab manuals and recent Australian consensus guidance summarize current best practice. WHO | Regional Office for Africa+2WHO | Regional Office for Africa+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 06, 2025.